Xarelto vs Eliquis - Pfizer/BMS win....

Discussion in 'Ortho-McNeil' started by Anonymous, Jun 23, 2011 at 3:06 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Re: Pradaxa > Xarelto > Eliquis = who will win?

    In your previous post #13, you said that patients have a 40% compliance, meaning they have a 60% non-compliance. Now you quote a study showing 30% with no comparasons. Those 2 numbers are a long way off. Which one do you prefer 30 or 60%, or should you just make up another number that makes you feel good.
     

  2. Anonymous

    Anonymous Guest

    Re: Pradaxa > Xarelto > Eliquis = who will win?

    seriously, get a life dude
     
  3. Anonymous

    Anonymous Guest

    Please enlighten us Dr.
     
  4. Anonymous

    Anonymous Guest

    Don't you think you're being a bit abrasive to that person? Afterall the Xa's are so new, there isn't enough data out there to make such a clear cut declaration about Xa's causing more bleeding in certain indications, they are still in trials.

    Oh, and before you jump on me, yes, I know, there are completed trials out there and they make no such declaration.
     
  5. Anonymous

    Anonymous Guest

    If someone is going to sell a new drug they damn better be capable of knowing the differences between them. That used to be what a good sales rep. looks like. I know that most of the reps. in this business are basically clueless, and are only concerned with the vomit repeating of a detail piece. That should never be considered good enough, esp. since the reps. hired for the CV specialty positions are supposed to be some of the best. If J&J is not concerned about hiring people that can function intelligently they are going to have a hard time in this division since there will be at least 3 competitors in the market by 2012, and 4 by 2013. You can pretend all you want, but little nuances between classes will make a big difference in a soon to be crowded market. FYI, for those who bother to come to cafepharma should know that the data was reported heavily on this website. Yes, you heard me, completed trials about both Riva and Apixaban on this site. Laziness does not equal quality.
     
  6. Anonymous

    Anonymous Guest

    Damn - this is funny sh_t! Predicting the future of yet unreleased drugs. Take a chill pill as there will be no clear winner for 2 more years. The person getting all worked up over data analysis is such a "TOOL". I feel sorry for that person as they will be on Cafe Pharma instead of watching fireworks with their family! But then again, that person is working at Home Depot as they previously lost their job with J&J.
     
  7. Dr. Phil

    Dr. Phil Guest

    It sounds like your taking this discussion a bit more serious than what it was intended based on my reading. Help me with this, isn't it outside of package insert to make a head to head or PI to PI claim? It is.
    You really can't say much more than what is allowed or in the insert by the FDA. Of course you would expect to be knowledgeable of the other articles but for customer discussion, it is limited, right? It is.

    Oh, and to claim what has been heavily reported/discussed at CP doesn't much make a good argument for could be used in a clinical argument. It's kinda like Wikipedia.
     
  8. Anonymous

    Anonymous Guest

    Right, did you get this by calling 1-800-psychic. We should all be watching fireworks continue to help burn all those states in the south expriencing a severe drought. J&J does not expect much out of their workers.
     
  9. Anonymous

    Anonymous Guest

    Would someone in the training dept. please inform this fool that when a product shows superiority in clinical trials over a comparator on primary endpoints, then you can most definitely and legally make superiority claims, esp. if it is adopted on guidelines as superior. This is info. from clinical trials, not PI's. Man you people are a piece of work.
     
  10. Anonymous

    Anonymous Guest

    Dufus, do you ever think to stop long enough to read the home page of cafepharma before you make a beeline to the company threads. Junior, you may learn something.
     
  11. Anonymous

    Anonymous Guest

    Have you seen the training dept lately? Maybe you better explain it to them first.
     
  12. Anonymous

    Anonymous Guest

    How 'bout after any of these drugs are launched it will be cake to write. Orthos don't give a crap about a pill. They cut.

    Can anyone say "Want do you want for lunch?"

    Out! Signed, Ex-Primary Care Hospital rep wannabe
     
  13. Anonymous

    Anonymous Guest

    Re: Pradaxa > Xarelto > Eliquis = who will win?

    With that rational neither Pradaxa or Eliquis should have performed better than QD warfarin with its long half life
     
  14. Anonymous

    Anonymous Guest

    Xarelto belongs to class of drugs known as Factor Xa inhibitors. Pfizer and Bristol-Myers Squibb Co. have co-developed another Factor Xa, apixaban. Last week, they released limited results of a clinical trial that some analysts interpreted as suggesting that apixaban was superior to Xarelto, though the drugs weren't compared head-to-head.
     
  15. Anonymous

    Anonymous Guest

    A little late to the dance, aren't you. Look up 10+ previous posts, and you would have gotten this information.
     
  16. Anonymous

    Anonymous Guest

    Pradaxa vs. Xarelto vs. Eliquis = GAME ON

    Let the games begin.
    Xarelto will not hit full stride until December with SPAF. Only then will we know how good Xarelto really is.
     
  17. Anonymous

    Anonymous Guest

    The news is the latest in the blood-clot drug race. Pfizer and Bristol-Myers Squibb's Eliquis, the yet-to-be-approved drug, recently aced a late-stage trial, performing far beyond analysts' expectations. The drug was more effective at preventing strokes than the old standby warfarin--and safer, too. That means Eliquis patients were less likely to develop bleeding problems than those using the older drug. Xarelto is equivalent to--not better than--warfarin on safety and efficacy, as Forbes has noted. But it is a once-a-day drug.
     
  18. Anonymous

    Anonymous Guest

    when the docs get comfortable with the new generation, QD will prevail over BID...no question...from a physicians point of view
     
  19. Anonymous

    Anonymous Guest

    Wrong. Still no antidote. Longer washout time before elective surgery which is a nuisance. Same thing with emergency surgery. Endoxaban will be the only XA with an antidote out the bag.
     
  20. Anonymous

    Anonymous Guest

    Wow, things can really change in a month can't they?


    Anti-Clotting Drug May Cause Severe Bleeding With No Benefit - (Yahoo!Health via NewsPoints Desk)
    (Ref: Yahoo!Health)
    July 24th, 2011

    http://www.firstwordpharma.com/node/891607